Quick Answer
LeonaBio, Inc. reported Operating Income Loss of -$102.27 million for the year ending 2025.
- LeonaBio, Inc. showed a decrease of -1.4% in Operating Income Loss from 2024 to 2025.
- This data is from LeonaBio, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$1.54 million | Q1 2020: -$1.27 million | Q2 2020: -$2.25 million | Q3 2020: -$7.40 million | Q1 2021: -$10.78 million | Q2 2021: -$16.64 million | Q3 2021: -$17.83 million | Q1 2022: -$23.39 million | Q2 2022: -$23.57 million | Q3 2022: -$24.13 million | Q1 2023: -$29.77 million | Q2 2023: -$31.64 million | Q3 2023: -$35.04 million | Q1 2024: -$27.69 million | Q2 2024: -$28.03 million | Q3 2024: -$29.62 million | Q1 2025: -$9.54 million | Q2 2025: -$7.29 million | Q3 2025: -$6.87 million.
- Over the full 7 years of available data (2019 to 2025), LeonaBio, Inc.'s Operating Income Loss has declined by 1,776.8%.
- Historical annual values: Fiscal year 2025: -$102.27 million | Fiscal year 2024: -$100.90 million | Fiscal year 2023: -$125.47 million | Fiscal year 2022: -$104.02 million | Fiscal year 2021: -$64.02 million | Fiscal year 2020: -$20.00 million | Fiscal year 2019: -$5.45 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: